Cover image for Vol. 122 Issue 21

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.649

ISI Journal Citation Reports © Ranking: 2015: 26/213 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

  1. Editorial

    1. Cervical cancer screening: How do we make sense of it all and what is the right balance?

      Warner K. Huh and Jeffrey C. Andrews

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30276

      Cervical cancer screening is arguably one of the greatest achievements in women's health care and cancer control within the last 50 years. However, screening recommendations have changed considerably over the past 5 years. This editorial discusses new evidence regarding the importance of viewing screening tests as a continuum and not individually, as well as future challenges and concerns regarding how to best screen women. See also pages 000-000.

  2. Original Articles

    1. Discipline

      The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

      Michelle I. Silver, Mark Schiffman, Barbara Fetterman, Nancy E. Poitras, Julia C. Gage, Nicolas Wentzensen, Thomas Lorey, Walter K. Kinney and Philip E. Castle

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30277

      The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus infections and related minor abnormalities. Human papillomavirus/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. The results of the current study indicate that repeated cotesting at 3-year intervals lowers population rates of cancer, but leads to a greater number of colposcopy examinations required to detect a single precancer. See also pages 000-000.

    2. Disease Site

      Genitourinary Disease
      Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening

      Ryan Hutchinson, Abdulhadi Akhtar, Justin Haridas, Deepa Bhat, Claus Roehrborn and Yair Lotan

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30330

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

      In a whole-institution sample of prostate-specific antigen ordering, researchers at the University of Texas Southwestern Medical Center have found no change in overall prostate-specific antigen ordering, but patients are being referred to urology providers at significantly higher average prostate-specific antigen values. The implications for prostate cancer outcomes from these trends warrant further research into provider variables associated with actual PSA utilization.

  3. Editorial

    1. Prostate cancer screening: Do guidelines matter?

      James T. Kearns and John L. Gore

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30331

      The prostate-specific antigen practices reported by Hutchinson et al in this issue of Cancer may reflect an isolated persistence of prostate-specific antigen ordering behaviors in a local health system due to other broader reports. However, it also raises an important issue: what is the appropriate level of screening and referral? Could continued but more thoughtful prostate-specific antigen screening and urology referral lead to better health outcomes among men with prostate cancer? See also pages 000-000.

  4. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

      Farhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, Elias Jabbour, Tapan Kadia, Sherry Pierce, Mark Brandt, Sa Wang, Sergej Konoplev, Xuemei Wang, Xuelin Huang, Naval Daver, Courtney DiNardo, Michael Andreeff, Marina Konopleva, Zeev Estrov, Guillermo Garcia-Manero, Jorge Cortes and Hagop Kantarjian

      Version of Record online: 22 SEP 2016 | DOI: 10.1002/cncr.30361

      • image
      • image
      • image

      Minimal residual disease assessment by multiparameter flow cytometry after induction and consolidation has significant prognostic value for patients with acute myeloid leukemia. According to a multivariate analysis, persistent minimal residual disease is the most important predictor of relapse-free and overall survival.

    2. Discipline

      Supportive Care
      The health care experience of patients with cancer during the last year of life: Analysis of the SEER-CAHPS data set

      Michael T. Halpern, Matthew P. Urato and Erin E. Kent

      Version of Record online: 21 SEP 2016 | DOI: 10.1002/cncr.30319

      • image
      • image

      In the current study, the authors examine factors associated with health care experience among patients with cancer during their last year of life using patient-reported information from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Medicare Survey linked to clinical data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (the SEER-CAHPS data set). Patient general and mental health status, Medicare insurance type (fee-for-service vs managed care), and sociodemographic characteristics are significantly associated with patients self-reported experience with health plans, physicians, and aspects of medical care.

    3. Outcomes Research
      Relation of comorbidities and patient navigation with the time to diagnostic resolution after abnormal cancer screening

      Elizabeth M. Whitley, Peter C. Raich, Donald J. Dudley, Karen M. Freund, Electra D. Paskett, Steven R. Patierno, Melissa Simon, Victoria Warren-Mears, Frederick R. Snyder and for the Patient Navigation Research Program Investigators

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30316

      • image
      • image
      • image

      A secondary analysis of data from the Patient Navigation Research Program reveals that navigation is effective in reducing delays in cancer diagnostic resolution among those with more than 1 comorbidity, who have the longest delays in care. Because patient navigation has been developed to improve the coordination of care, patient navigation may be particularly effective for patients with comorbidities.

    4. Disease Site

      Head and Neck Disease
      National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma

      David J. Sher, Chad C. Rusthoven, Saad A. Khan, Mary Jo Fidler, Hong Zhu and Matthew Koshy

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30255

      • image

      Although the majority of patients with lymph node-positive oropharyngeal squamous cell carcinoma are treated with concurrent chemoradiotherapy, significant disparities appear to exist with regard to its use, because nonwhite and female patients, as well as those without private insurance, are significantly less likely to receive systemic therapy as part of their treatment plan. In addition, despite an absence of data supporting the use of induction chemotherapy and national guidelines recommending definitive chemoradiotherapy as the treatment of choice for these patients, neoadjuvant chemotherapy continues to be frequently delivered. Additional research is necessary both to understand these disparities as well as to define the motivation for using induction chemotherapy.

    5. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

      Antonio Jimeno, Marshall R. Posner, Lori J. Wirth, Nabil F. Saba, Roger B. Cohen, Elizabeta C. Popa, Athanassios Argiris, Kenneth F. Grossmann, Ammar Sukari, Dawn Wilson, Xiaosha Zhang, Jade Sun, Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Susan S. Pandya and Jared Weiss

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30317

      • image

      Activin receptor-like kinase 1 (ALK1), a type I receptor of the TGF-β superfamily, is expressed on activated endothelial cells in squamous cell carcinoma of the head and neck and is critical in several stages of angiogenesis, particularly those involved in blood vessel maturation and stabilization. The authors report a trial of dalantercept, a receptor fusion protein that acts as a ligand trap to block ALK1 signaling in patients with relapsed/metastatic squamous cell carcinoma of the head and neck.

    6. Genitourinary Disease
      Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

      Yohann Loriot, Karim Fizazi, Johann S. de Bono, David Forer, Mohammad Hirmand and Howard I. Scher

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30336

      • image
      • image
      • image
      • image

      Patients with metastatic, castration-resistant prostate cancer and visceral metastases, such as liver or lung metastases, have a worse prognosis than those with nonvisceral metastases. Enzalutamide-treated patients with liver or lung metastases have better outcomes than those who receive placebo.

  5. Editorial

    1. Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo

      Nicole G. Chau and Robert I. Haddad

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30352

      Antiangiogenic therapies as single agents have failed to demonstrate significant antitumor activity in heavily pretreated, unselected populations with recurrent/metastatic head and neck squamous cell carcinoma. Much work is needed to evaluate rational strategies for combining antiangiogenic agents with other systemic therapies or with radiotherapy for head and neck squamous cell carcinoma to move the field forward. See also pages 000-000.

  6. Original Articles

    1. Disease Site

      Breast Disease
      Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene

      Valentina Silvestri, Veronica Zelli, Virginia Valentini, Piera Rizzolo, Anna Sara Navazio, Anna Coppa, Simona Agata, Cristina Oliani, Daniela Barana, Tiziana Castrignanò, Alessandra Viel, Antonio Russo, Maria Grazia Tibiletti, Ines Zanna, Giovanna Masala, Laura Cortesi, Siranoush Manoukian, Jacopo Azzollini, Bernard Peissel, Bernardo Bonanni, Paolo Peterlongo, Paolo Radice, Domenico Palli, Giuseppe Giannini, Giovanni Chillemi, Marco Montagna and Laura Ottini

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30337

      • image
      • image

      This study highlights the important role of partner and localizer of BRCA2 (PALB2) in high-risk, BRCA1/2 mutation–negative male breast cancer cases and indicates that male breast cancer may be helpful in the identification of PALB2 families. PALB2 seems now to be ready for clinical translation, and families with male breast cancer cases should be considered for PALB2 genetic testing with the aim of improving the clinical management of breast cancer patients and their relatives.

  7. Review Articles

    1. Current management and future directions in metastatic pancreatic adenocarcinoma

      Anna M. Varghese, Maeve A. Lowery, Kenneth H. Yu and Eileen M. O'Reilly

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30342

      • image

      The management of patients with metastatic pancreatic cancer has evolved within the last 5 years due to the approval of several new combination regimens. A growing understanding of the complex role and interplay of the immune system, tumor stroma, and molecular biology of this disease has poised the field for meaningful change in the proximate future.

    2. Immunotherapy for prostate cancer: False promises or true hope?

      Brian T. Rekoske and Douglas G. McNeel

      Version of Record online: 20 SEP 2016 | DOI: 10.1002/cncr.30250

      • image

      In this review, the authors highlight the history of immunotherapeutic development for prostate cancer and many of the strategies currently being explored. They conclude that immunotherapies have promise for improving clinical outcomes, and that the greatest benefits will come as immunotherapy approaches begin to be rationally combined with other therapies.

  8. Correspondence

  9. Original Articles

    1. Disease Site

      Genitourinary Disease
      Management trends for men with early stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database

      Adam B. Weiner, Shane M. Pearce and Scott E. Eggener

      Version of Record online: 14 SEP 2016 | DOI: 10.1002/cncr.30332

      • image
      • image

      Postorchiectomy surveillance for early stage nonseminomatous germ cell tumor of the testicle may reduce treatment-related morbidities without compromising cancer-specific survival. In the United States, nearly 75% of men with clinical stage IA and nearly 50% of men with clinical stage IB disease received surveillance in 2012 and 2013, and recent increases are observed in men with clinical stage IA tumors.

  10. Correspondence

    1. Reply to Nomograms need to be presented in full

      Horace C.W. Choi, Wei Xu and Anne W.M. Lee

      Version of Record online: 14 SEP 2016 | DOI: 10.1002/cncr.30345

    2. Nomograms need to be presented in full

      Gary S. Collins and Yannick Le Manach

      Version of Record online: 14 SEP 2016 | DOI: 10.1002/cncr.30347

  11. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Biliary cancer: Utility of next-generation sequencing for clinical management

      Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan, Daniel Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed Kaseb, Vincent Miller, Philip J. Stephens, Funda Meric-Bernstam, Rachna Shroff and Jeffrey Ross

      Version of Record online: 13 SEP 2016 | DOI: 10.1002/cncr.30254

      • image
      • image
      • image
      • image
      • image
      • image
      • image

      This is the largest clinically annotated data set of biliary tract cancer cases with comprehensive genomic profiling, and it indicates the potential of comprehensive genomic profiling to improve outcomes. Comprehensive genomic profiling should be strongly considered in the management of patients with biliary tract cancer.